Moeun Son
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Moeun Son has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
Emily S. Miller
6 shared publicationsWilliam A. Grobman
Division of Maternal Fetal Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL
5 shared publicationsJennifer F. Culhane
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, USA
4 shared publicationsArchana Roy
3 shared publicationsCaitlin Partridge
Joint Data Analytics Team Yale School of Medicine New Haven Connecticut USA
3 shared publications- Emily S. Miller
Northwestern University Feinberg School of Medicine, Chicago, IL
3 shared publications
Latest Publications
- 1 November 2026
- Published by Wiley in Transfusion
Trends and determinants of peripartum blood transfusions
Background: Blood transfusion is critical in mitigating blood loss during delivery, but the epidemiology of peripartum blood transfusion in the United States is not fully understood. The objective of this study was to estimate trends in peripartum blood transfusions, including severe hemorrhage, and identify transfusion risk factors. Study Design and Methods: A retrospective cohort was assembled from the Recipient Epidemiology and Donor Study IV Pediatric (REDS‐IV‐P) database, which includes a network of hospitals and blood centers across four U.S. regional hubs. This included in‐hospital deliveries ≥24 weeks gestation from 2019 to 2024, with the outcome being any peripartum (within ±7 days of delivery) blood product transfusion. Bayesian Model Averaging (BMA) was used to examine associations. Results: There were 158,322 deliveries, with transfusion occurring in 4246 (11% were severe hemorrhage). Overall incidence of transfusion increased from ~2% early in the study period to ~3% in later years ( p < 0.001). The odds of peripartum transfusion were higher for deliveries where patients had an underlying hemoglobinopathy (adjusted odds ratio [aOR] [95% confidence interval; CI] aOR = 3.35 [2.65, 4.24]), venous thromboembolism (aOR = 3.25 [2.47, 4.26]), received hemostatic factor (aOR = 10.30 [9.58, 11.06]), mechanical ventilation (aOR = 13.91 [8.76, 22.11]), or hysterectomy (aOR = 13.68 [9.86, 18.96]). Conclusion: Peripartum transfusions are increasing across the REDS‐IV‐P hubs and are associated with underlying medical‐obstetric risk factors such as bleeding disorders and hemoglobinopathies. Our findings support the importance of early prenatal healthcare and identification of conditions that may help prevent peripartum hemorrhage and associated transfusions.
- 1 November 2026
- Published by Wiley in Transfusion
Trends and determinants of peripartum blood transfusions
Background: Blood transfusion is critical in mitigating blood loss during delivery, but the epidemiology of peripartum blood transfusion in the United States is not fully understood. The objective of this study was to estimate trends in peripartum blood transfusions, including severe hemorrhage, and identify transfusion risk factors. Study Design and Methods: A retrospective cohort was assembled from the Recipient Epidemiology and Donor Study IV Pediatric (REDS‐IV‐P) database, which includes a network of hospitals and blood centers across four U.S. regional hubs. This included in‐hospital deliveries ≥24 weeks gestation from 2019 to 2024, with the outcome being any peripartum (within ±7 days of delivery) blood product transfusion. Bayesian Model Averaging (BMA) was used to examine associations. Results: There were 158,322 deliveries, with transfusion occurring in 4246 (11% were severe hemorrhage). Overall incidence of transfusion increased from ~2% early in the study period to ~3% in later years ( p < 0.001). The odds of peripartum transfusion were higher for deliveries where patients had an underlying hemoglobinopathy (adjusted odds ratio [aOR] [95% confidence interval; CI] aOR = 3.35 [2.65, 4.24]), venous thromboembolism (aOR = 3.25 [2.47, 4.26]), received hemostatic factor (aOR = 10.30 [9.58, 11.06]), mechanical ventilation (aOR = 13.91 [8.76, 22.11]), or hysterectomy (aOR = 13.68 [9.86, 18.96]). Conclusion: Peripartum transfusions are increasing across the REDS‐IV‐P hubs and are associated with underlying medical‐obstetric risk factors such as bleeding disorders and hemoglobinopathies. Our findings support the importance of early prenatal healthcare and identification of conditions that may help prevent peripartum hemorrhage and associated transfusions.
- Open Access
Categorizing differences in postpartum hemorrhage management and associated clinical factors
Objective: To examine whether there is variation in postpartum hemorrhage (PPH) management and whether differences are associated with patient‐level factors and delivery hospital. Methods: This is a retrospective cohort study of patients delivered at ≥20 weeks of gestation at any of four hospitals within one Connecticut healthcare system, with evidence of PPH, and receipt of intervention from 2012 to 2023. Patients with placenta accreta spectrum disorders, obstetric anal sphincter injuries, or stillbirth were excluded. The primary dependent variable was type of PPH treatment administered and structured as a four‐level categorical variable: (1) usual care treatment including synthetic oxytocin infusion and uterine massage; (2) receipt of less aggressive medication treatment with uterotonics only; (3) receipt of more aggressive medication treatment with uterotonics only; and (4) any procedure with or without medication use. Although hysterectomy is considered a later‐stage procedure in the setting of PPH, patients undergoing hysterectomy were included in the procedure group because insufficient cases of hysterectomy did not allow separate grouping. Maternal sociodemographic, clinical and pregnancy factors, and delivery hospital site were compared across the four‐level PPH treatment categories. Bivariate analyses and crude and adjusted multinomial logistic regression analyses were performed. Results: Of 110,690 delivery encounters, 10,829 (9.8%) had documented evidence of study‐defined PPH. Of these deliveries, 10,075 (93.0%) met eligibility criteria and were included in the analysis: 4941 (49.0%) received usual care treatment, 2982 (29.6%) received less aggressive medication use only, 1308 (13.0%) received more aggressive medication use only, and 844 (8.4%) underwent procedure(s) with or without medication use. There was a wide range in the number of medication types and doses received, as well as a wide spectrum of the number and types of procedures employed. Adjusted multinomial logistic regression analyses showed significant differences in patient‐level factors (e.g., maternal age, race and ethnicity, gestational age, placenta previa, hypertensive disorders, and in vitro fertilization [IVF]) and delivery hospital among different types of PPH management. Conclusion: There is significant variation in the management of PPH, and differences are associated with patient‐level factors and delivery hospital type and region, which may be a proxy for clinical management and available resources.
Open AccessCategorizing differences in postpartum hemorrhage management and associated clinical factors
Objective: To examine whether there is variation in postpartum hemorrhage (PPH) management and whether differences are associated with patient‐level factors and delivery hospital. Methods: This is a retrospective cohort study of patients delivered at ≥20 weeks of gestation at any of four hospitals within one Connecticut healthcare system, with evidence of PPH, and receipt of intervention from 2012 to 2023. Patients with placenta accreta spectrum disorders, obstetric anal sphincter injuries, or stillbirth were excluded. The primary dependent variable was type of PPH treatment administered and structured as a four‐level categorical variable: (1) usual care treatment including synthetic oxytocin infusion and uterine massage; (2) receipt of less aggressive medication treatment with uterotonics only; (3) receipt of more aggressive medication treatment with uterotonics only; and (4) any procedure with or without medication use. Although hysterectomy is considered a later‐stage procedure in the setting of PPH, patients undergoing hysterectomy were included in the procedure group because insufficient cases of hysterectomy did not allow separate grouping. Maternal sociodemographic, clinical and pregnancy factors, and delivery hospital site were compared across the four‐level PPH treatment categories. Bivariate analyses and crude and adjusted multinomial logistic regression analyses were performed. Results: Of 110,690 delivery encounters, 10,829 (9.8%) had documented evidence of study‐defined PPH. Of these deliveries, 10,075 (93.0%) met eligibility criteria and were included in the analysis: 4941 (49.0%) received usual care treatment, 2982 (29.6%) received less aggressive medication use only, 1308 (13.0%) received more aggressive medication use only, and 844 (8.4%) underwent procedure(s) with or without medication use. There was a wide range in the number of medication types and doses received, as well as a wide spectrum of the number and types of procedures employed. Adjusted multinomial logistic regression analyses showed significant differences in patient‐level factors (e.g., maternal age, race and ethnicity, gestational age, placenta previa, hypertensive disorders, and in vitro fertilization [IVF]) and delivery hospital among different types of PPH management. Conclusion: There is significant variation in the management of PPH, and differences are associated with patient‐level factors and delivery hospital type and region, which may be a proxy for clinical management and available resources.
- 1 September 2026
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 148 (3) , 306-308
Moving Toward Standardization of Prophylactic Oxytocin Dosing in the Third Stage of Labor
Was not provided for this article.
- 1 September 2026
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 148 (3) , 306-308
Moving Toward Standardization of Prophylactic Oxytocin Dosing in the Third Stage of Labor
Was not provided for this article.
- Open Access
- 13 July 2026
- Published by Elsevier in The Journal of Pediatrics
- Vol. 297, 115236
Trends in Postmenstrual Age at Discharge and Predictive Factors Among a Contemporary Cohort of Infants Born Preterm
- 13 July 2026
- Published by Elsevier in The Journal of Pediatrics
- Vol. 297, 115236
Open AccessTrends in Postmenstrual Age at Discharge and Predictive Factors Among a Contemporary Cohort of Infants Born Preterm
- Open Access
- 2 June 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (6) , e1004653
Prognostic value of cervical length for spontaneous preterm birth in asymptomatic women with singleton pregnancy: An individual participant data meta-analysis
Background: Spontaneous preterm birth (SPTB) is the leading cause of perinatal and early childhood mortality worldwide. Studies have generally suggested that mid-trimester transvaginal sonographic cervical length n = 91,404). Mean cervical length was 40 mm (standard deviation [SD] 9 mm) at about 20 weeks’ gestation. SPTB <37 weeks occurred in 4,442 (5.2%) participants. An L-shape non-linear association between cervical length and SPTB was observed. A longer cervical length was associated with steeply lower odds of SPTB until it reached 40 mm, beyond which the odds of SPTB became stable. This means that compared to a woman with a cervical length of 40 mm, those with a cervical length of 20 and 30 mm were associated 6.22 and 2.10 higher odds of SPTB (95% confidence intervals [4.76, 8.13] and [1.85, 2.38]), respectively. Limitations included suboptimal data retrieval rate (51% of all eligible participants) and a lack of comprehensive co-predictors of SPTB across all datasets. Conclusion: We found a non-linear association between cervical length and SPTB. We found a non-linear association between cervical length and SPTB. Shorter cervix is associated with progressively higher risk of SPTB when length is less than 40 mm, but probability of term birth is high when cervical length is over 40 mm.
- 2 June 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (6) , e1004653
Open AccessPrognostic value of cervical length for spontaneous preterm birth in asymptomatic women with singleton pregnancy: An individual participant data meta-analysis
Background: Spontaneous preterm birth (SPTB) is the leading cause of perinatal and early childhood mortality worldwide. Studies have generally suggested that mid-trimester transvaginal sonographic cervical length n = 91,404). Mean cervical length was 40 mm (standard deviation [SD] 9 mm) at about 20 weeks’ gestation. SPTB <37 weeks occurred in 4,442 (5.2%) participants. An L-shape non-linear association between cervical length and SPTB was observed. A longer cervical length was associated with steeply lower odds of SPTB until it reached 40 mm, beyond which the odds of SPTB became stable. This means that compared to a woman with a cervical length of 40 mm, those with a cervical length of 20 and 30 mm were associated 6.22 and 2.10 higher odds of SPTB (95% confidence intervals [4.76, 8.13] and [1.85, 2.38]), respectively. Limitations included suboptimal data retrieval rate (51% of all eligible participants) and a lack of comprehensive co-predictors of SPTB across all datasets. Conclusion: We found a non-linear association between cervical length and SPTB. We found a non-linear association between cervical length and SPTB. Shorter cervix is associated with progressively higher risk of SPTB when length is less than 40 mm, but probability of term birth is high when cervical length is over 40 mm.
- 19 May 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (7) , 1043-1044
How Big Is the “Gray Area”? Navigating Health-Threatening Previability Pregnancy Complications in States With Abortion Restrictions
- 19 May 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (7) , 1043-1044
How Big Is the “Gray Area”? Navigating Health-Threatening Previability Pregnancy Complications in States With Abortion Restrictions
- 5 May 2026
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 8 (7) , 101982
Perceptions of respiratory syncytial virus vaccination among a publicly insured pregnant cohort
- 5 May 2026
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 8 (7) , 101982
Perceptions of respiratory syncytial virus vaccination among a publicly insured pregnant cohort
- Top Cited PapersOpen Access
Neonatal impact of maternal biomarker screening for risk of preterm birth with targeted interventions (PRIME): A multicenter, randomized, controlled trial
Background: Preterm birth remains a leading cause of neonatal morbidity and mortality, yet clinicians possess limited tools to identify at‐risk pregnancies and implement effective interventions. This study evaluated whether knowledge of a mid‐second‐trimester maternal blood biomarker test result, combined with an intervention bundle for those identified as being at higher risk, improves neonatal outcomes in a population at low overall risk for spontaneous preterm birth. Methods: PRIME was a multicenter, randomized, controlled trial at 19 US sites. Participants with singleton pregnancies at 18–20 6/7 weeks’ gestation underwent biomarker testing with the previously validated insulin‐like growth factor‐binding protein 4 to sex hormone‐binding globulin (IGFBP4/SHBG) ratio and were randomized to an open‐label screen‐guided care arm or a blinded routine care arm. Higher‐risk participants in the screen‐guided care arm received a bundled intervention consisting of daily vaginal progesterone, low‐dose aspirin, and weekly telephonic nurse support. The co‐primary outcomes, analyzed in an intent‐to‐treat population, were: (1) a composite index of neonatal morbidity and mortality and (2) neonatal hospital length of stay. Additional outcomes were gestational age at birth, neonatal intensive care unit (NICU) admissions, and NICU length of stay. Outcomes were adjusted for parity, pre‐enrollment aspirin use, and COVID positivity. Recruitment was halted for efficacy at the interim analysis, and all enrolled participants were followed to delivery and neonatal outcome assessment. Results: The enrolled population included 5018 participants with delivery data available for 4806, comprising the intent‐to‐treat population (2416 screen‐guided care, 2390 routine care). Screen‐guided care was associated with reduced composite neonatal morbidity (odds ratio [OR], 0.80; 95% confidence interval [CI], 0.66–0.96; p = 0.015), shortened neonatal hospital stays (incidence rate ratio [IRR], 0.95; 95% CI, 0.92–0.98; p = 0.004), and fewer NICU admissions. Conclusion: In low‐risk pregnancies, care guided by a maternal IGFBP4/SHBG blood test with targeted interventions improved neonatal outcomes. These findings suggest a potential role for IGFBP4/SHBG screen‐guided care in enhancing early risk detection and informing strategies to reduce events related to preterm birth. Trial Registration: ClinicalTrials.gov identifier: NCT04301518
Top Cited PapersOpen AccessNeonatal impact of maternal biomarker screening for risk of preterm birth with targeted interventions (PRIME): A multicenter, randomized, controlled trial
Background: Preterm birth remains a leading cause of neonatal morbidity and mortality, yet clinicians possess limited tools to identify at‐risk pregnancies and implement effective interventions. This study evaluated whether knowledge of a mid‐second‐trimester maternal blood biomarker test result, combined with an intervention bundle for those identified as being at higher risk, improves neonatal outcomes in a population at low overall risk for spontaneous preterm birth. Methods: PRIME was a multicenter, randomized, controlled trial at 19 US sites. Participants with singleton pregnancies at 18–20 6/7 weeks’ gestation underwent biomarker testing with the previously validated insulin‐like growth factor‐binding protein 4 to sex hormone‐binding globulin (IGFBP4/SHBG) ratio and were randomized to an open‐label screen‐guided care arm or a blinded routine care arm. Higher‐risk participants in the screen‐guided care arm received a bundled intervention consisting of daily vaginal progesterone, low‐dose aspirin, and weekly telephonic nurse support. The co‐primary outcomes, analyzed in an intent‐to‐treat population, were: (1) a composite index of neonatal morbidity and mortality and (2) neonatal hospital length of stay. Additional outcomes were gestational age at birth, neonatal intensive care unit (NICU) admissions, and NICU length of stay. Outcomes were adjusted for parity, pre‐enrollment aspirin use, and COVID positivity. Recruitment was halted for efficacy at the interim analysis, and all enrolled participants were followed to delivery and neonatal outcome assessment. Results: The enrolled population included 5018 participants with delivery data available for 4806, comprising the intent‐to‐treat population (2416 screen‐guided care, 2390 routine care). Screen‐guided care was associated with reduced composite neonatal morbidity (odds ratio [OR], 0.80; 95% confidence interval [CI], 0.66–0.96; p = 0.015), shortened neonatal hospital stays (incidence rate ratio [IRR], 0.95; 95% CI, 0.92–0.98; p = 0.004), and fewer NICU admissions. Conclusion: In low‐risk pregnancies, care guided by a maternal IGFBP4/SHBG blood test with targeted interventions improved neonatal outcomes. These findings suggest a potential role for IGFBP4/SHBG screen‐guided care in enhancing early risk detection and informing strategies to reduce events related to preterm birth. Trial Registration: ClinicalTrials.gov identifier: NCT04301518
- Open Access
The perspectives of Maternal‐Fetal Medicine first‐year fellows and fellowship program directors on fellowship start date
Introduction: There is increasing support for an August 1 start date for Maternal‐Fetal Medicine (MFM) fellowship training programs, but there are concerns of unintended consequences related to the change.Methods: Two anonymous cross‐sectional surveys were administered in‐person and electronically to first‐year MFM fellows (October 25–27, 2024) and program directors (PDs) (January 29 to February 12, 2025). Fellows provided demographic information about themselves and their programs, their actual and ideal start dates, and whether they encountered financial or non‐financial challenges or health insurance coverage gaps. Fellows who considered their ideal start date to be in the month of July were compared to those who chose a date in the months of August or later. PDs were asked about their program's current and ideal start dates and to rate the importance of various factors in deciding their start date. Both cohorts were asked how important they thought a program's start date was in influencing an applicant's rank list and how important it was for all programs to have the same start date. Descriptive statistics using chi‐square tests were performed with a significance level of p < 0.05.Results: There were 112 (77.8%) of 144 first‐year fellows and 95 (88.8%) of 107 PDs who completed surveys. Start dates varied with 52.7% of fellows responding that they started on August 1. A total of 81 (72.3%) fellows moved to a new city or state, 54 (69.2%) reported health insurance coverage gaps, and 70 (65.4%) reported some financial impact during their transition. Still, most fellows (90.6%, 96/106) considered a start date other than July 1 ideal, with 74.6% of respondents choosing August 1 as their ideal date. For PDs, potential financial challenges and health insurance gaps for the fellow were the most important factors in determining their program's start date. When asked what they considered the ideal start date, 35.8% of PDs still chose July 1. Several PDs cited institutional constraints, disruptions to research coursework, and concern for work visa holders as important considerations for their chosen start date.Conclusion: The majority opinion of surveyed first‐year MFM fellows supports delaying the fellowship start date, but there are important unintended consequences that must be addressed.
Open AccessThe perspectives of Maternal‐Fetal Medicine first‐year fellows and fellowship program directors on fellowship start date
Introduction: There is increasing support for an August 1 start date for Maternal‐Fetal Medicine (MFM) fellowship training programs, but there are concerns of unintended consequences related to the change.Methods: Two anonymous cross‐sectional surveys were administered in‐person and electronically to first‐year MFM fellows (October 25–27, 2024) and program directors (PDs) (January 29 to February 12, 2025). Fellows provided demographic information about themselves and their programs, their actual and ideal start dates, and whether they encountered financial or non‐financial challenges or health insurance coverage gaps. Fellows who considered their ideal start date to be in the month of July were compared to those who chose a date in the months of August or later. PDs were asked about their program's current and ideal start dates and to rate the importance of various factors in deciding their start date. Both cohorts were asked how important they thought a program's start date was in influencing an applicant's rank list and how important it was for all programs to have the same start date. Descriptive statistics using chi‐square tests were performed with a significance level of p < 0.05.Results: There were 112 (77.8%) of 144 first‐year fellows and 95 (88.8%) of 107 PDs who completed surveys. Start dates varied with 52.7% of fellows responding that they started on August 1. A total of 81 (72.3%) fellows moved to a new city or state, 54 (69.2%) reported health insurance coverage gaps, and 70 (65.4%) reported some financial impact during their transition. Still, most fellows (90.6%, 96/106) considered a start date other than July 1 ideal, with 74.6% of respondents choosing August 1 as their ideal date. For PDs, potential financial challenges and health insurance gaps for the fellow were the most important factors in determining their program's start date. When asked what they considered the ideal start date, 35.8% of PDs still chose July 1. Several PDs cited institutional constraints, disruptions to research coursework, and concern for work visa holders as important considerations for their chosen start date.Conclusion: The majority opinion of surveyed first‐year MFM fellows supports delaying the fellowship start date, but there are important unintended consequences that must be addressed.
- Open Access
- 11 February 2025
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 25 (1) , 1-9
Association between isolated abnormal 1-hour glucose challenge test and adverse pregnancy outcomes: a retrospective review from an urban tertiary care center in the United States
Background: The objective of this study was to investigate whether an isolated abnormal 1-hour glucose challenge test (GCT) among patients without gestational diabetes (GDM) is associated with adverse outcomes. Methods: This is a retrospective cohort study of patients who underwent GDM screening at ≥ 24 weeks’ gestation with a 1-hour GCT and delivered a singleton fetus at > 35 weeks’ gestation at an urban tertiary hospital from 1/2013 to 10/2021. Data were extracted from an electronic medical record data warehouse using standardized billing/diagnosis codes. Individuals were categorized into 3 groups: normal screening (1-hour GCT value < 140 mg/dL), intermediate screening (1-hour GCT value ≥ 140 and < 200 but normal 3-hour glucose tolerance test (GTT)), and GDM (1-hour GCT ≥ 200 mg/dL or abnormal 3-hour GTT). The primary composite perinatal morbidity outcome included any of the following: large for gestational age (LGA) birthweight, birth injury, hypoglycemia with neonatal intensive care unit (NICU) admission, respiratory distress syndrome, transient tachypnea of the newborn, apnea, NICU admission, or perinatal death. Multiple secondary outcomes were also evaluated. Bivariable analyses and multivariable logistic regression modeling were performed. Results: Of 37,277 eligible patients, 29,698 (79.7%) had normal screening results, 5092 (13.7%) had intermediate screening results, and 2487 (6.6%) were diagnosed with GDM. There were significant differences in baseline characteristics between the three groups, including age, parity, race and ethnicity, payer-type, obesity, and pre-pregnancy metformin use. Compared to normal screening, intermediate screening was associated with an increased risk for the composite perinatal morbidity outcome (OR 1.23, 95% CI 1.15–1.32), cesarean (OR 1.37, 95% CI 1.28–1.46), and hypertensive disorders of pregnancy (OR 1.30, 95% CI 1.20–1.40). Associations for these outcomes were further pronounced in those with GDM compared to normal screening (OR 1.86, 95% CI 1.70–2.03; OR 1.69, 95% CI 1.56–1.84; and OR 1.57, 95% CI 1.42–1.74, respectively). After adjusting for potential confounders, increased risks for the composite perinatal morbidity outcome persisted for those with intermediate screening (aOR 1.18, 95% CI 1.10–1.26). Conclusions: In addition to patients with GDM, individuals an isolated abnormal 1-hour GCT without GDM were also at increased risks for adverse pregnancy outcomes. Further investigation is needed to understand if patients with mild dysregulation may still benefit from other interventions.
- 11 February 2025
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 25 (1) , 1-9
Open AccessAssociation between isolated abnormal 1-hour glucose challenge test and adverse pregnancy outcomes: a retrospective review from an urban tertiary care center in the United States
Background: The objective of this study was to investigate whether an isolated abnormal 1-hour glucose challenge test (GCT) among patients without gestational diabetes (GDM) is associated with adverse outcomes. Methods: This is a retrospective cohort study of patients who underwent GDM screening at ≥ 24 weeks’ gestation with a 1-hour GCT and delivered a singleton fetus at > 35 weeks’ gestation at an urban tertiary hospital from 1/2013 to 10/2021. Data were extracted from an electronic medical record data warehouse using standardized billing/diagnosis codes. Individuals were categorized into 3 groups: normal screening (1-hour GCT value < 140 mg/dL), intermediate screening (1-hour GCT value ≥ 140 and < 200 but normal 3-hour glucose tolerance test (GTT)), and GDM (1-hour GCT ≥ 200 mg/dL or abnormal 3-hour GTT). The primary composite perinatal morbidity outcome included any of the following: large for gestational age (LGA) birthweight, birth injury, hypoglycemia with neonatal intensive care unit (NICU) admission, respiratory distress syndrome, transient tachypnea of the newborn, apnea, NICU admission, or perinatal death. Multiple secondary outcomes were also evaluated. Bivariable analyses and multivariable logistic regression modeling were performed. Results: Of 37,277 eligible patients, 29,698 (79.7%) had normal screening results, 5092 (13.7%) had intermediate screening results, and 2487 (6.6%) were diagnosed with GDM. There were significant differences in baseline characteristics between the three groups, including age, parity, race and ethnicity, payer-type, obesity, and pre-pregnancy metformin use. Compared to normal screening, intermediate screening was associated with an increased risk for the composite perinatal morbidity outcome (OR 1.23, 95% CI 1.15–1.32), cesarean (OR 1.37, 95% CI 1.28–1.46), and hypertensive disorders of pregnancy (OR 1.30, 95% CI 1.20–1.40). Associations for these outcomes were further pronounced in those with GDM compared to normal screening (OR 1.86, 95% CI 1.70–2.03; OR 1.69, 95% CI 1.56–1.84; and OR 1.57, 95% CI 1.42–1.74, respectively). After adjusting for potential confounders, increased risks for the composite perinatal morbidity outcome persisted for those with intermediate screening (aOR 1.18, 95% CI 1.10–1.26). Conclusions: In addition to patients with GDM, individuals an isolated abnormal 1-hour GCT without GDM were also at increased risks for adverse pregnancy outcomes. Further investigation is needed to understand if patients with mild dysregulation may still benefit from other interventions.